This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.
Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992–2001.
Boehm A, Sperr WR, Leitner G, Worel N, Oehler L, Jaeger E et al. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest 2008; 38: 945–952.
Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M et al. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) predicts survival and non-relapse mortality in lymphoma and myeloma patients undergoing reduced-intensity or non-myeloablative allogeneic stem cell transplantations. Blood 2008; 112: 746, no. 2144, (abstract).
Fujimaki K, Sakai R, Fujisawa S, Fujita H, Tanaka M, Hagihara M et al. Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation [Japanese]. Gan to Kagaku Ryoho [Japn J Cancer Chemother] 2008; 35: 87–91.
Lim ZY, Ingram W, Brand R, Ho A, Kenyon M, Devereux S et al. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplant 2010; 45: 633–639.
Guilfoyle R, Demers A, Bredeson C, Richardson E, Rubinger M, Szwajcer D . et al. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 2009; 43: 133–139.
Majhail NS, Brunstein CG, McAvoy S, Defor TE, Al-Hazzouri A, Setubal D et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant 2008; 14: 985–992.
Sorror ML, Storer B, Storb RF . Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences (Letter to the Editor). Biol Blood Marrow Transplant 2009; 15: 757–758.
Defor TE, Majhail NS, Weisdorf DJ, Brunstein CG, McAvoy S, Arora M et al. A modified comorbidity index for hematopoietic cell transplantation. Bone Marrow Transplant 2010; 45: 933–938.
Acknowledgements
This study was supported by grants HL36444, CA78902, CA18029, CA15704 and HL088021 from the National Institutes of Health, Bethesda, MD. We thank Helen Crawford, Bonnie Larson, Karen Carbonneau and Sue Carbonneau for their assistance with manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Sorror, M., Storer, B. & Storb, R. Assignment of scores for the hematopoietic cell transplantation comorbidity index: integer vs exact weights. Bone Marrow Transplant 46, 464–466 (2011). https://doi.org/10.1038/bmt.2010.131
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.131
This article is cited by
-
Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2016)